Click for best price
Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Share 2023
The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. This report aims to provide a comprehensive presentation of the global market for Resistant Pseudomonas Aeruginosa Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Resistant Pseudomonas Aeruginosa Infections Drugs. This report contains market size and forecasts of Resistant Pseudomonas Aeruginosa Infections Drugs in global, including the following market information:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Sales, 2018-2023, 2024-2032, (K Pcs)
Global top five Resistant Pseudomonas Aeruginosa Infections Drugs companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Semi-Synthetic Penicillin Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma and Shionogi & Co Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Type, 2022 (%)
- Semi-Synthetic Penicillin
- Cephalosporin
- Lactam Drugs
- Others
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Application, 2022 (%)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues share in global market, 2022 (%)
- Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
- Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- ContraFect Corp
- Inhibrx LP
- Achaogen Inc
- LegoChem Biosciences Inc
- Melinta Therapeutics Inc
- Novartis AG
- AmpliPhi Biosciences Corp
- Biolytics Pharma
- Shionogi & Co Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Resistant Pseudomonas Aeruginosa Infections Drugs, market overview.
Chapter 2: Global Resistant Pseudomonas Aeruginosa Infections Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Resistant Pseudomonas Aeruginosa Infections Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Resistant Pseudomonas Aeruginosa Infections Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
73 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Overall Market Size
2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size: 2022 VS 2030
2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales: 2018-2030
3 Company Landscape
3.1 Top Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.2 Top Global Resistant Pseudomonas Aeruginosa Infections Drugs Companies Ranked by Revenue
3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Companies
3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Companies
3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Resistant Pseudomonas Aeruginosa Infections Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.8.1 List of Global Tier 1 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Markets, 2022 & 2030
4.1.2 Semi-Synthetic Penicillin
4.1.3 Cephalosporin
4.1.4 Lactam Drugs
4.1.5 Others
4.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
4.2.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2023
4.2.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2024-2030
4.2.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
4.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
4.3.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2023
4.3.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2024-2030
4.3.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
4.4 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Home Care
5.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
5.2.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2023
5.2.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2024-2030
5.2.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
5.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
5.3.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2023
5.3.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2024-2030
5.3.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
5.4 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2022 & 2030
6.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
6.2.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2023
6.2.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2024-2030
6.2.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
6.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
6.3.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2023
6.3.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2024-2030
6.3.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030
6.4.2 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2030
6.4.3 US Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.4.4 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.4.5 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030
6.5.2 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2030
6.5.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.5 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.6 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.7 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.8 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.5.9 Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030
6.6.2 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2030
6.6.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.6.4 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.6.5 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.6.6 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.6.7 India Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030
6.7.2 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2030
6.7.3 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.7.4 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2018-2030
6.8.3 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.8.4 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.8.5 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
6.8.6 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 ContraFect Corp
7.1.1 ContraFect Corp Company Summary
7.1.2 ContraFect Corp Business Overview
7.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.1.5 ContraFect Corp Key News & Latest Developments
7.2 Inhibrx LP
7.2.1 Inhibrx LP Company Summary
7.2.2 Inhibrx LP Business Overview
7.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Inhibrx LP Key News & Latest Developments
7.3 Achaogen Inc
7.3.1 Achaogen Inc Company Summary
7.3.2 Achaogen Inc Business Overview
7.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Achaogen Inc Key News & Latest Developments
7.4 LegoChem Biosciences Inc
7.4.1 LegoChem Biosciences Inc Company Summary
7.4.2 LegoChem Biosciences Inc Business Overview
7.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.4.5 LegoChem Biosciences Inc Key News & Latest Developments
7.5 Melinta Therapeutics Inc
7.5.1 Melinta Therapeutics Inc Company Summary
7.5.2 Melinta Therapeutics Inc Business Overview
7.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Melinta Therapeutics Inc Key News & Latest Developments
7.6 Novartis AG
7.6.1 Novartis AG Company Summary
7.6.2 Novartis AG Business Overview
7.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Novartis AG Key News & Latest Developments
7.7 AmpliPhi Biosciences Corp
7.7.1 AmpliPhi Biosciences Corp Company Summary
7.7.2 AmpliPhi Biosciences Corp Business Overview
7.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.7.5 AmpliPhi Biosciences Corp Key News & Latest Developments
7.8 Biolytics Pharma
7.8.1 Biolytics Pharma Company Summary
7.8.2 Biolytics Pharma Business Overview
7.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Biolytics Pharma Key News & Latest Developments
7.9 Shionogi & Co Ltd
7.9.1 Shionogi & Co Ltd Company Summary
7.9.2 Shionogi & Co Ltd Business Overview
7.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Shionogi & Co Ltd Key News & Latest Developments
8 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, Analysis
8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, 2018-2030
8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Resistant Pseudomonas Aeruginosa Infections Drugs Supply Chain Analysis
10.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Value Chain
10.2 Resistant Pseudomonas Aeruginosa Infections Drugs Upstream Market
10.3 Resistant Pseudomonas Aeruginosa Infections Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Resistant Pseudomonas Aeruginosa Infections Drugs in Global Market
Table 2. Top Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
Table 9. List of Global Tier 1 Resistant Pseudomonas Aeruginosa Infections Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2018-2023
Table 15. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2024-2030
Table 16. By Application ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2018-2023
Table 20. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2024-2030
Table 21. By Region ? Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2018-2023
Table 25. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), 2024-2030
Table 26. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2024-2030
Table 30. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2024-2030
Table 34. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2024-2030
Table 38. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2024-2030
Table 42. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, (K Pcs), 2024-2030
Table 46. ContraFect Corp Company Summary
Table 47. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 48. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. ContraFect Corp Key News & Latest Developments
Table 50. Inhibrx LP Company Summary
Table 51. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 52. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Inhibrx LP Key News & Latest Developments
Table 54. Achaogen Inc Company Summary
Table 55. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 56. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Achaogen Inc Key News & Latest Developments
Table 58. LegoChem Biosciences Inc Company Summary
Table 59. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 60. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. LegoChem Biosciences Inc Key News & Latest Developments
Table 62. Melinta Therapeutics Inc Company Summary
Table 63. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 64. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Melinta Therapeutics Inc Key News & Latest Developments
Table 66. Novartis AG Company Summary
Table 67. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 68. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Novartis AG Key News & Latest Developments
Table 70. AmpliPhi Biosciences Corp Company Summary
Table 71. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 72. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. AmpliPhi Biosciences Corp Key News & Latest Developments
Table 74. Biolytics Pharma Company Summary
Table 75. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 76. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Biolytics Pharma Key News & Latest Developments
Table 78. Shionogi & Co Ltd Company Summary
Table 79. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Offerings
Table 80. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Shionogi & Co Ltd Key News & Latest Developments
Table 82. Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 83. Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 84. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region, 2018-2023 (K Pcs)
Table 85. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region, 2024-2030 (K Pcs)
Table 86. Resistant Pseudomonas Aeruginosa Infections Drugs Market Opportunities & Trends in Global Market
Table 87. Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers in Global Market
Table 88. Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints in Global Market
Table 89. Resistant Pseudomonas Aeruginosa Infections Drugs Raw Materials
Table 90. Resistant Pseudomonas Aeruginosa Infections Drugs Raw Materials Suppliers in Global Market
Table 91. Typical Resistant Pseudomonas Aeruginosa Infections Drugs Downstream
Table 92. Resistant Pseudomonas Aeruginosa Infections Drugs Downstream Clients in Global Market
Table 93. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type in 2022
Figure 2. Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application in 2022
Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Global Market: 2018-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2022
Figure 9. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 11. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 12. By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs), 2018-2030
Figure 13. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 15. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 16. By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs), 2018-2030
Figure 17. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 20. By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 21. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 22. By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 23. US Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 28. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 37. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 43. By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 44. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2018-2030
Figure 48. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$, Mn), 2018-2030
Figure 52. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity (K Pcs), 2018-2030
Figure 53. The Percentage of Production Resistant Pseudomonas Aeruginosa Infections Drugs by Region, 2022 VS 2030
Figure 54. Resistant Pseudomonas Aeruginosa Infections Drugs Industry Value Chain
Figure 55. Marketing Channels
